Senaparib: First Approval

Arnold Lee

doi:10.1007/s40265-025-02200-1

2025-07-30

PRE

Arnold Lee *

DOI：10.1007/s40265-025-02200-1

原文链接

原文求助

摘要

En 中文

聚(ADP-核糖)聚合酶(PARP)抑制剂已在卵巢癌一线维持治疗中显示出无进展生存期获益。森普利(派舒宁®;赛纳帕利胶囊)是一种新型PARP抑制剂，能强力抑制PARP1和PARP2，由艾普迈康医药公司开发用于治疗晚期卵巢癌和小细胞肺癌。本文总结了森普利开发中的关键里程碑，最终获得针对一线铂类化疗后达到完全或部分缓解的晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌成人患者的维持治疗首项批准。

期刊

Drugs

IF:

14.4

论文数:

8.4K

被引数:

2.3W

机构

暂无机构信息

引用论文

A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors

CANCER

IF5.1

2023-01-31

OAAI

Gao, Bo; Voskoboynik, Mark; Cooper, Adam; Wilkinson, Kate; Hoon, Siao; Hsieh, Chih-Yi; Cai, Suixiong; Tian, Ye Edward; Bao, Jun; Ma, Ning; Wang, Chen; Zhang, Ming; Li, Baoyue; Guo, Mingchuan; Zhou, Ruiyu; Wang, Xiaozhu; Xu, Cong; de Souza, Paul

PARP Inhibitors in Ovarian Cancer: A Review

TARGETED ONCOLOGY

IF4

2023-06-03

OAAI

O'Malley, David M.; Krivak, Thomas C.; Kabil, Nashwa; Munley, Jiefen; Moore, Kathleen N.

Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial

NATURE MEDICINE

IF50

2024-05-15

PREAI

Wu, Xiaohua; Liu, Jihong; Wang, Jing; Wang, Li; Lin, Zhongqiu; Wang, Xiaobin; Zhu, Jianqing; Kong, Beihua; Fei, Junwei; Tang, Ying; Xia, Bairong; Liang, Zhiqing; Wang, Ke; Huang, Yi; Zheng, Hong; Lin, An; Jiang, Kui; Wang, Wei; Wang, Xin; Lou, Ge; Pan, Hongming; Yao, Shuzhong; Li, Guiling; Hao, Min; Cai, Yunlang; Chen, Xuejun; Yang, Zhijun; Chen, Youguo; Wen, Hongwu; Qu, Pengpeng; Xu, Cong; Hsieh, Chih-Yi

The Discovery of a Potent PARP1 Inhibitor Senaparib

MOLECULAR CANCER THERAPEUTICS

IF5.5

2024-06-26

PREAI

Cai, Sui X.; Ma, Ning; Wang, Xiaozhu; Guo, Mingchuan; Jiang, Yangzhen; Tian, Ye E.

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial

The Oncologist

IF0

2023-06-20

OAAI

Junning Cao; Hongqian Guo; Dongmei Ji; Weina Shen; Shun Zhang; Chih-Yi Hsieh; Sui Xiong Cai; Ye Edward Tian; Cong Xu; Pin Zhang; Binghe Xu

SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Wu, X.; Liu, J.; Wang, L.; Lin, Z.; Wang, J.; Wang, C.; Kong, B.; Liang, Z.; Cheng, Y.; Wen, H.; Lou, G.; Huang, Y.; Wang, K.; An, R.; Zhu, J.; Zhou, H.; Yue, Y.

MA18.11 A Phase Ib/II Study of Senaparib in Combination with Low-dose Temozolomide: Updated Results in Relapsed ES-SCLC Patients

Journal of Thoracic Oncology

IF0

2023-11-01

PREAI

Hong,M.H.; Gao,B.; Cheng,Y.; Shim,B.-Y.; Johnson,M.; Liu,C.-Y.; Kim,S.-W.; Lee,K.H.; Zielinski,R.; Eek,R.; Hu,S.; Lin,C.-C.; Chung,W.-P.; Hsieh,C.-Y.; Cai,S.X.; Tian,Y.E.; Liu,L.; Niu,T.; Halcro,C.; Li,B.; Zhang,M.; Zhang,C.; Li,H.; Xu,L.; Hung,H.T.

没有更多内容